What question did this study set out to answer?

To compare baseline symptom burden by race among women with early-stage breast cancer prior to chemotherapy and quantify disparities explained by baseline characteristics.

June 1, 2021JAMA Network OpenOpen Access

Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

XHXin HuAmerican Cancer Society PCPuneet Kaur ChehalEmory Healthcare CKCameron M. KaplanKeck Hospital of USC

Discussion

Member takes

Implication

Cross-sectional study reveals disparate prechemotherapy symptom burdens between Black and White women with breast cancer, highlighting factors that may drive treatment tolerance disparities.

Key Points

To compare baseline symptom burden by race among women with early-stage breast cancer prior to chemotherapy and quantify disparities explained by baseline characteristics.
Conducted a cross-sectional study of 1338 women (420 Black [31.4%] and 918 White [68.6%]; mean age 54.6 years) with stage I to III, hormone receptor-positive breast cancer at a Southern US cancer center from 2007 to 2015.
Assessed four symptom composite scores (general physical symptoms, treatment adverse effects, acute distress, and despair) graded on a 0 to 10 scale before chemotherapy initiation.
Applied Blinder-Oaxaca decomposition to evaluate the proportion of symptom disparities explained by baseline sociodemographic and clinical characteristics.
Prior to starting chemotherapy, Black women reported a statistically significantly higher composite score for adverse effects compared with White women (44.5 vs 43.8) but a significantly lower acute distress score (48.5 vs 51.0).
Decomposition analysis showed that baseline characteristics in Black patients were associated with greater symptom burden across all four domains, but these differences were offset by statistically significant, unexplained physical, distress, and despair symptom reporting in White patients.

Cite This Study

Hu et al. (2021) studied this question.

synapsesocial.com/papers/6a709eac2163a0a01bc4d701 https://doi.org/10.1001/jamanetworkopen.2021.12076

View Full Paper

Ask AI

Bookmark

Implication

Cross-sectional study reveals disparate prechemotherapy symptom burdens between Black and White women with breast cancer, highlighting factors that may drive treatment tolerance disparities.

Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Characterization of Clinical Symptoms by Race Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer Before Starting Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider